GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-2,709 Cr |
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2,709 Cr | Negative | |
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹62,359.1 Cr | -5.4% | -10.3% | 16.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,483.0 Cr | -3.2% | -7.8% | 9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹249,248.0 Cr | 1% | 0.9% | 67.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,822.0 Cr | -1.8% | -4.8% | 32.2% | Stock Analytics | |
| CIPLA | ₹105,427.0 Cr | -3.1% | -6.5% | -12.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,492.3 Cr | -1.7% | 3.1% | -3.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -5.4% |
-10.3% |
16.8% |
| SENSEX | -1.2% |
-6.4% |
-10.8% |
You may also like the below Video Courses